Hengrui Pharmaceuticals Investment Quality Review (600276.SH)

Quality score: 64/100 Valuation position: current price/base FV 3.28 Final signal: AVOID

Core Conclusion

Hengrui Pharmaceuticals is AVOID. Current price of CNY54.08 is far above base FV of CNY16.48, and the 64/100 quality score is below the watch threshold. Conservative/base/optimistic FV is CNY15.65/CNY16.48/CNY20.59.

Business And Quality

Five-year revenue CAGR is 5.1%, and latest-year FCF is CNY8.27bn. The report recognizes cash flow and net cash, but policy pressure, R&D productivity, margin uncertainty, and evidence requirements cap the quality score.

Financial Audit

The review uses fiscal 2021-2025 in CNY and a 1.7% CNY 10Y government-bond yield dated 2026-07-31. Five-year FCF/Net Income is 0.81 and OCF/Net Income is 1.19. Latest net cash is CNY40.88bn.

Valuation

The FV range is based on normalized FCF and separate balance-sheet adjustments. Price/base FV of 3.28 fails the margin-of-safety test and leaves no 2x base-case support.

Buy And Monitor

Current action is avoid. Reconsideration requires quality score above 75, price/base FV below 0.70, and clearer evidence that R&D, pricing, and cash flow can compound without structural pressure.

Risks

Risks include drug-price policy pressure, R&D execution, product concentration, margin compression, accounting or capitalization questions, and cash-flow volatility. Weak FCF conversion would reduce FV further.

Sources

Sources are public quote and financial data platforms, company filings or IR, ChinaBond for the CNY risk-free rate, and public FX data where applicable. Research only, not personalized investment advice.